Viral genomic RNA (gRNA)

Viral genomic RNA (gRNA) serves as the complete genetic material for RNA viruses, encompassing positive-sense, negative-sense, and double-stranded RNA configurations (NIH, 2022). It functions as the primary template for both the synthesis of viral proteins and the replication of the viral genome, often utilizing viral-encoded enzymes like RNA-dependent RNA polymerase (RdRp) (Nature Reviews Drug Discovery, 2020). In the context of drug development, genomic RNA is a high-value target; therapeutic strategies include the use of nucleoside analogs to disrupt replication, as well as antisense oligonucleotides and small molecules designed to target highly conserved structural motifs (PubChem, 2024). These interventions are critical for treating a wide array of viral diseases, including COVID-19, Hepatitis C, and Influenza (PubMed, 2021). However, the inherent plasticity of RNA genomes allows for rapid evolution, necessitating the monitoring of viral resistance and the development of combination therapies to maintain clinical efficacy (StatPearls, 2023).

Other names

Viral genomevRNARNA genomeViral RNA

Inhibition of viral replication through chain termination, induction of lethal mutagenesis, or direct degradation via RNA interference and antisense mechanisms (PubChem, 2024; Nature Reviews Drug Discovery, 2020).